All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

298

2015 to 2026

Breakthrough

116

Accelerated

79

Priority review

229

Orphan

298

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
2015147
201682
2017175
20182512
2019176
2020239
2021207
20221110
20231911
20241710
2025195
2026168

298 approvals

Newest first. Hover a badge for what it means.

  • Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026
    Original approval · BLA 761488NovelOrphan

    To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

  • Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
    Original approval · NDA 220963NovelPriority reviewOrphanApproval letter

    To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

  • Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
    Original approval · NDA 221198NovelPriority reviewOrphanApproval letter

    To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

  • Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
    Original approval · NDA 220425NovelPriority reviewOrphanApproval letter

    To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

  • Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
    Original approval · BLA 761463NovelPriority reviewOrphanApproval letter

    To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

  • Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
    Original approval · NDA 218592NovelPriority reviewOrphanApproval letter

    To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

  • Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
    Original approval · NDA 220210NovelPriority reviewOrphanApproval letter

    To treat Alexander disease in pediatric and adult patients

  • Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
    Original approval · NDA 220605NovelPriority reviewOrphanApproval letter

    To treat erythrocytosis in adults with polycythemia vera

  • Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
    Original approval · NDA 220106NovelPriority reviewOrphanApproval letter

    To treat dermatomyositis in adults

  • Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
    Original approval · NDA 220910NovelPriority reviewOrphanApproval letter

    To treat metastatic pancreatic cancer

  • Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
    Original approval · BLA 761508NovelPriority reviewOrphanApproval letter

    To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

  • Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
    Original approval · NDA 221075NovelPriority reviewOrphanApproval letter

    To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

  • Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
    Original approval · NDA 220860NovelPriority reviewOrphanApproval letter

    To treat narcolepsy type 1

  • Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
    Original approval · NDA 220185NovelOrphanApproval letter

    To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

  • Ambelvist (Gadoquatrane) · Bayer HealthcareJun 12, 2026
    Original approval · NDA 219627NovelOrphanApproval letter

    To detect and visualize lesions with abnormal vascularity, in conjunction with MRI

  • Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INCMay 27, 2026
    Original approval · BLA 761460NovelPriority reviewOrphanApproval letter

    To treat adults with blastic plasmacytoid dendritic cell neoplasm

  • Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026
    Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

  • Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026
    Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCMar 26, 2026
    Original approval · BLA 761326NovelOrphanApproval letter
  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026
    Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Lynavoy (Linerixibat) · InterceptMar 17, 2026
    Original approval · NDA 220295NovelOrphanApproval letter

    To treat cholestatic pruritus associated with primary biliary cholangitis

  • Yuviwel (Navepegritide) · AscendisFeb 27, 2026
    Original approval · NDA 219164NovelAccelerated approvalPriority reviewOrphanApproval letter

    To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

  • Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026
    Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

  • Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
    Original approval · NDA 211241NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat Menkes disease

  • Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
    Original approval · BLA 761152NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

  • Myqorzo (Aficamten) · CytokineticsDec 19, 2025
    Original approval · NDA 219083NovelBreakthrough therapyOrphanApproval letter

    To treat symptomatic obstructive hypertrophic cardiomyopathy

  • Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025
    Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

  • Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
    Original approval · NDA 219947NovelBreakthrough therapyOrphanApproval letter

    To reduce triglycerides in adults with familial chylomicronemia syndrome

  • Komzifti (Ziftomenib) · KuraNov 13, 2025
    Original approval · NDA 220305NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

  • Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
    Original approval · NDA 219792NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

  • Ferabright (Ferumoxytol) · AzurityOct 16, 2025
    Original approval · NDA 219868NovelOrphanApproval letter
  • Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
    Original approval · NDA 218764NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat idiopathic pulmonary fibrosis

  • Palsonify (Paltusotine Hydrochloride) · CrineticsSep 25, 2025
    Original approval · NDA 219070NovelOrphanApproval letter

    To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

  • Forzinity (Elamipretide Hydrochloride) · Stealth BiotherapsSep 19, 2025
    Original approval · NDA 215244NovelAccelerated approvalPriority reviewOrphanApproval letter

    To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

  • Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
    Original approval · NDA 219685NovelOrphanApproval letter

    To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

  • Dawnzera (Autoinjector) (Donidalorsen Sodium) · Ionis Pharms INCAug 21, 2025
    Original approval · NDA 219407NovelOrphanApproval letter

    To prevent attacks of hereditary angioedema

  • Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
    Original approval · NDA 219876NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy

  • Sephience (Sepiapterin) · Ptc TherapJul 28, 2025
    Original approval · NDA 219666NovelOrphanApproval letter

    To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet

  • Ekterly (Sebetralstat) · KalvistaJul 3, 2025
    Original approval · NDA 219301NovelOrphanApproval letter

    To treat acute attacks of hereditary angioedema

  • Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc.Jul 2, 2025
    Original approval · BLA 761400NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody

  • Andembry (Garadacimab-Gxii) · Csl Behring LLCJun 16, 2025
    Original approval · BLA 761367NovelOrphanApproval letter

    To prevent attacks of hereditary angioedema

  • Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
    Original approval · NDA 219713NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer

  • Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025
    Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy

  • Imaavy (Nipocalimab-Aahu) · Janssen BiotechApr 29, 2025
    Original approval · BLA 761430NovelPriority reviewOrphanApproval letter

    To treat generalized myasthenia gravis

  • Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
    Original approval · BLA 761258NovelBreakthrough therapyOrphanApproval letter

    In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy

  • Qfitlia (Fitusiran Sodium) · Genzyme CorpMar 28, 2025
    Original approval · NDA 219019NovelOrphanApproval letter

    To prevent or reduce the frequency of bleeding episodes in hemophilia A or B

  • Gomekli (Mirdametinib) · SpringworksFeb 11, 2025
    Original approval · NDA 219379NovelPriority reviewOrphanApproval letter

    To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection

  • Grafapex (Treosulfan) · MedexusJan 21, 2025
    Original approval · NDA 214759NovelOrphanApproval letter

    For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

  • Alhemo (Concizumab-Mtci) · Novo Nordisk INCDec 20, 2024
    Original approval · BLA 761315NovelPriority reviewOrphanApproval letter

    For routine prophylaxis to prevent bleeding episodes in hemophilia A and B

  • Alyftrek (Deutivacaftor, Tezacaftor, Vanzacaftor Calcium) · Vertex Pharms INCDec 20, 2024
    Original approval · NDA 218730NovelPriority reviewOrphanApproval letter

    For the treatment of cystic fibrosis (CF) in patients 6 years of age and older

Page 1 of 6Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.